Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.
Press releases published on September 4, 2025
Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
GlobeNewswire
·
September 4, 2025
Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action that normalizes VEGF expression. End of study, 40-week …
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
GlobeNewswire
·
September 4, 2025
Regen’s Approach Could Be Paradigm Shift in Supportive Oncology Care SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) today announced its ongoing efforts to expand the clinical development of HemaXellerate, its novel …
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, …
PathAI Expands Clinical Leadership - Announcing Partnerships with Mindpeak, Stratipath, and Primaa
GlobeNewswire
·
September 4, 2025
BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered digital pathology solutions and the developer of the market-leading AISight Dx1 Image Management System (IMS), today announced new partnerships with three cutting-edge AI …
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
GlobeNewswire
·
September 4, 2025
CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being …
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
GlobeNewswire
·
September 4, 2025
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus. The solution enables clinical and statistical programmers to efficiently create …
Alignment Health Earns Spot on Newsweek’s World’s Most Trustworthy Companies 2025 List for Third Consecutive Year
GlobeNewswire
·
September 4, 2025
ORANGE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alignment Health has been recognized as one of Newsweek’s World’s Most Trustworthy Companies for the third consecutive year. Presented in collaboration with Statista, the award honors companies that earn …
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
GlobeNewswire
·
September 4, 2025
WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound …
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire
·
September 4, 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic …
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
GlobeNewswire
·
September 4, 2025
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope …
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
GlobeNewswire
·
September 4, 2025
Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), …
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
GlobeNewswire
·
September 4, 2025
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no …
Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System
GlobeNewswire
·
September 4, 2025
Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin grafting More than $42,000 per patient cost savings, together with improved patient …
A Race Against Blindness Awards Additional $1 Million Grant to Advance Clinical Trial for Sight-Saving Gene Therapy for Bardet-Biedl Syndrome 1 (BBS1)
GlobeNewswire
·
September 4, 2025
PHOENIX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, announced today that it has awarded a new $1.0 million grant to Axovia Therapeutics to …
CorVista Health Announces Publication of Real-World Case Series in the Journal of the American College of Cardiology Exploring its Non-Invasive Test for Earlier Diagnosis of Pulmonary Hypertension
GlobeNewswire
·
September 4, 2025
BETHESDA, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the publication of a new case series in the Journal of the American College of Cardiology (JACC), showcasing real-world clinical applications of the CorVista System®, a novel …
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious …
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, …
AeroChamber2Go® Valved Holding Chamber Now Available at Walmart Pharmacy: A Game-Changer for On-the-Go Inhaler Users
GlobeNewswire
·
September 4, 2025
PLATTSBURGH, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Monaghan Medical is proud to announce the AeroChamber2Go® Valved Holding Chamber (VHC) is now available at 4,400 Walmart Pharmacy locations across the United States. Available by prescription, this …
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
GlobeNewswire
·
September 4, 2025
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA’s …